TRANSGENE (EPA:TNG) | WebDisclosure

PRESS RELEASE

published on 11/06/2025 at 08:30, 6 months 5 days ago

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Transgene to present VacDesignR® tool at ESMO-AI 2025 for optimized cancer vaccine design. Tool enhances virus efficiency and yield for individualized therapies

Cancer Vaccines Computational Tool Transgene VacDesignR ESMO-AI 2025
BRIEF

published on 11/04/2025 at 17:55, 6 months 6 days ago

Transgene presents its progress and financial situation as of Q3 2025

Funding Immunotherapy Transgene TG4050 SITC 2025
BRIEF

published on 11/04/2025 at 17:55, 6 months 6 days ago

Transgene présente ses avancées et sa situation financière au T3 2025

Financement Immunothérapie Transgene TG4050 SITC 2025
PRESS RELEASE

published on 11/04/2025 at 17:50, 6 months 6 days ago

Transgene Provides Business and Financial Update for Q3 2025
Transgene provides business and financial update for Q3 2025, including immunogenicity data of INTV TG4050 in Phase I study on HNSCC. Company focuses on cancer immunotherapies

Financial Update Transgene INTV TG4050 Cancer Immunotherapies HNSCC
PRESS RELEASE

published on 11/04/2025 at 17:50, 6 months 6 days ago

Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2025
Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2025, notamment sur les avancées de son vaccin thérapeutique TG4050 contre le cancer de la tête et du cou

Cancer Situation Financière Transgene TG4050 Vaccin Thérapeutique
BRIEF

published on 10/20/2025 at 08:35, 6 months 22 days ago

Le BT-001 de Transgene et BioInvent présente une activité antitumorale prometteuse

Immunothérapie Contre Le Cancer Transgene Virus Oncolytique BT-001 Activité Antitumorale
BRIEF

published on 10/20/2025 at 08:35, 6 months 22 days ago

Transgene and BioInvent's BT-001 Shows Promising Antitumor Activity

Cancer Immunotherapy Transgene Oncolytic Virus BT-001 Antitumoral Activity
PRESS RELEASE

published on 10/20/2025 at 08:30, 6 months 22 days ago

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025

Transgene Oncolytic Virus BioInvent BT-001 Pembrolizumab
BRIEF

published on 06/13/2025 at 08:35, 10 months 28 days ago

Transgene s'engage auprès des principales plateformes de l'industrie biotechnologique

Immunothérapie Traitement Du Cancer Transgene Données Cliniques Réunions Biotech
BRIEF

published on 06/13/2025 at 08:35, 10 months 28 days ago

Transgene Engages with Key Biotech Industry Platforms

Cancer Treatment Clinical Data Immunotherapy Transgene Biotech Meetings

Published on 05/11/2026 at 14:30, 1 hour 58 minutes ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Published on 05/11/2026 at 14:00, 2 hours 28 minutes ago

Unusual Machines Accelerates Domestic Battery Manufacturing by Signing a Merger Agreement to Acquire Upgrade Energy
Published on 05/11/2026 at 14:00, 2 hours 28 minutes ago

New Horizon Aircraft Ltd. Announces Closing of $20 Million Offering of Common Shares
Published on 05/11/2026 at 14:00, 2 hours 28 minutes ago

Colosseum Bankable Feasibility Study Confirms High Margin Gold Project
Published on 05/11/2026 at 14:00, 2 hours 28 minutes ago

Ur-Energy Reminds Shareholders and Interested Parties of First Quarter Conference Call and Webcast

View all ACCESSWIRE

Published on 05/11/2026 at 15:55, 33 minutes ago

EQS-Adhoc: Accentro Real Estate AG announces deviation from the IDW S6 report and intended increase in the 2025/2027 bond
Published on 05/11/2026 at 15:46, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/11/2026 at 15:46, 42 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Published on 05/11/2026 at 15:45, 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 05/11/2026 at 15:44, 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc

View all EQS

Published on 05/11/2026 at 14:00, 2 hours 28 minutes ago

Droits de vote
Published on 05/11/2026 at 14:00, 2 hours 28 minutes ago

Voting rights
Published on 05/11/2026 at 10:48, 5 hours 40 minutes ago

GUILLEMOT CORPORATION | Weekly report share buyback from May 4 to May 8 2026
Published on 05/11/2026 at 10:48, 5 hours 40 minutes ago

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 4 au 8 mai 2026
Published on 05/11/2026 at 09:16, 7 hours 12 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 28 avril 2026

View all LES ECHOS COMFI WIRE

News